edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: CASI Pharmaceuticals
Edison Investment Research is terminating coverage on CASI Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
CASI Pharmaceuticals — 1 video in collection
CASI Pharmaceuticals is focused on building a portfolio of drugs which it intends to produce for Chinese and worldwide markets. Its products are focused on the hematology and oncology space, including its first product, Evomela, launched in China in 2019. The company is also developing an anti-CD19 CAR-T therapy, CNCT19, and the anti-CD38 drug CID-103, among others. The goal is to seek approval through new pathways that have opened in the quickly changing Chinese regulatory environment.
Get access to the very latest content matched to your personal investment style.